Abhijit Banerjee is a Professor in the Department of Economics at the Massachusetts Institute of Technology (MIT). His research focuses on development economics, public health policy, and social protection programs, particularly addressing poverty and inequality in low- and middle-income countries. He has conducted large-scale experiments evaluating interventions such as conditional cash transfers, universal basic income, and healthcare policies. Key areas of interest include the design and implementation of anti-poverty programs, behavioral economics, and the long-term health impacts of infectious diseases like COVID-19. His work often integrates experimental methods to assess policy effectiveness, with contributions to global health studies and economic development strategies. Notably, his research on the RECOVERY trial evaluates treatments for hospitalized COVID-19 patients, while other studies explore financial spillover effects of electronic government transfers in Indonesia and savings behavior interventions in Chile. Banerjee has collaborated on projects analyzing post-COVID-19 health outcomes, labor market dynamics in India, and the role of trusted messengers in public health communication during crises. Despite the breadth of his contributions, specific details about his educational background, grants, or lab affiliations are not explicitly provided in the source text.
Professor Hutan Ashrafian is a clinician-scientist and surgeon at the University of Leeds Business School, holding dual roles as Professor of Research Impact and Senior Research Fellow at Imperial College London. His expertise spans AI in healthcare, metabolic surgery, and ancient history. He pioneered STARD-AI and QUADAS-AI guidelines for AI diagnostics, collaborated on AI-driven breast cancer screening with Google and NHS, and led global health policy initiatives. Ashrafian’s work bridges medicine, history, and philosophy, including his contributions to understanding historical figures’ medical conditions, such as King Tutankhamun’s epilepsy. He has authored over 550 publications, 12 books, and holds a PhD in computational physiology and an MBA with distinction. Awards include the Hunterian Prize and Wellcome Trust Fellowship. His research also explores AI ethics, quantum physics paradoxes, and art-based medical diagnostics. Education: PhD in Computational Physiology (Imperial College London) MBA (Warwick Business School) MD (University College London) Bachelor of Science in Immunology (University College London) Research Interests: Ashrafian’s work spans: AI in Medicine: Diagnostic algorithms, guideline development (STARD-AI/QUADAS-AI), and ethical frameworks. Metabolic Surgery: Bariatric interventions, gut microbiome, and obesity treatments. Ancient History: Medical analyses of historical figures (e.g., Tutankhamun, Julius Caesar) and art-based pathology identification. Philosophy: AI rights (AIONAI law), temporal paradoxes, and the Simulation Argument. Awards: Royal College of Surgeons Arris and Gale Lectureship Hunterian Prize Wellcome Trust Research Fellowship Advising & Innovation: Supervised >50 PhD students, co-founded Oxford Medical Products (weight loss tech), and serves as CSO at Flagship Pioneering’s Preemptive Health division. He advises on NHS digital transformation and global health policy. Labs/Teams: Leads AI initiatives at Imperial’s Institute of Global Health Innovation and collaborates with Google, NICE, and international institutions on health tech solutions.
Dr. Carolyn Emery is a Professor in the Faculty of Kinesiology at the University of Calgary, with joint appointments in Pediatrics and Community Health Sciences at the Cumming School of Medicine. She holds leadership roles as Chair of the Sport Injury Prevention Research Centre (an International Olympic Committee Research Centre) and the Alberta Children’s Hospital Research Institute. Her affiliations include the McCaig Institute for Bone and Joint Health, Hotchkiss Brain Institute, and O’Brien Institute for Public Health. Dr. Emery’s education includes a BScPT from Queen’s University (1988), MSc in Epidemiology from the University of Calgary (1999), and PhD in Epidemiology from the University of Alberta (2004). Her research focuses on injury prevention in youth sports, concussion, and pediatric rehabilitation, aiming to reduce long-term health consequences such as osteoarthritis and post-concussion syndrome. She leads major grants including CIHR’s “SHRed Injuries” and NFL-funded concussion surveillance programs. Her research interests emphasize practical interventions for injury prevention, including neuromuscular training and policy changes. Recent work explores concussion outcomes in adolescents, biomechanical injury mechanisms, and global sport safety initiatives. She has published extensively on topics like sport-related musculoskeletal injuries, concussion management, and the epidemiology of youth sports. Dr. Emery has received over 20 awards, including the Royal Society of Canada Fellowship, Killam Professorship, and CIHR Canada Research Chair. Her work bridges clinical practice, policy, and community engagement to enhance public health outcomes in sports and youth recreation. Her lab, the Sport Injury Prevention Research Centre, collaborates internationally to develop evidence-based strategies for injury prevention. Current projects include evaluating the impact of tackle laws in rugby, head acceleration in wrestling, and long-term consequences of pediatric concussions.
Bobak Mortazavi is an Associate Professor in the Department of Computer Science & Engineering at Texas A&M University. His research focuses on medical analytics, machine learning, wearable sensors, and cyber-physical systems. He leads interdisciplinary projects in healthcare technology, including AI-driven diagnostics and predictive modeling for cardiovascular diseases. He has received notable awards such as the Best Demonstration Award at IEEE EMBS 2012 and the Best Paper Award at the Fourth International Conference on Data Analytics 2015. His work bridges machine learning with clinical applications, emphasizing practical solutions for healthcare challenges. Recent research includes developing AI tools for aortic stenosis detection, electrolyte estimation via ECG, and real-time patient monitoring systems. He collaborates with industry and academic partners to advance telemedicine and wearable health technologies. Key contributions include the SMART-LV project for smartphone-based cardiac diagnostics and the ArterialNet framework for blood pressure reconstruction using wearable sensors. His work is published in top journals like IEEE Journal of Biomedical and Health Informatics and Elsevier's Pervasive and Mobile Computing.
Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.
Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it
Elena Agapie is an Assistant Professor in the Department of Informatics at the Donald Bren School of Information & Computer Sciences, University of California, Irvine. Her research lies at the intersection of human-computer interaction (HCI), health, and behavior change, focusing on designing technologies that support individuals in adopting and maintaining healthy behaviors through human-centered approaches. She is affiliated with the Connected Learning Lab and the Institute for Future Health at UCI. Her educational background includes a PhD in Human Centered Design and Engineering from the University of Washington, an MS in Computer Science from Harvard University, and a BS in Computer Science from Jacobs University Bremen in Germany. She has also conducted research at Microsoft Research, FXPAL, Intel Labs, and NASA Jet Propulsion Lab. Elena's research focuses on designing tools that integrate evidence-based behavioral interventions with user needs, particularly in mental health, chronic disease management, and social support systems. She explores how technology can support therapist-client collaboration, enable tailored health interventions, and leverage crowd expertise for personalized behavior change plans. Her work often involves participatory design, qualitative studies, and prototyping of interactive systems for diverse populations, including youth, hospitalized patients, and underserved communities. Her recent publications, primarily in top-tier venues like CHI and CSCW, reflect a strong trend toward social computing in health, longitudinal behavior support, and the design of inclusive digital health tools. Key themes include goal setting, conversational agents, social sharing in health tracking, and cross-disciplinary collaboration in health technology development. Best Paper Award (top 1%) at CHI 2017 Honorable Mention Best Paper Award (top 5%) at CHI 2016 Best Paper Award (top 1%) at HCOMP 2015 Honorable Mention Best Paper Award (top 5%) at CHI 2013 Elena has been funded by the National Science Foundation, National Institutes of Health, and UCI internal grants. She actively mentors PhD students including Bruna Oewel, Meeshu Agnihotri, and Mehreen Masood, and is currently recruiting students interested in HCI, health, and behavior change. She previously led the outreach program in the HCDE department at the University of Washington, creating workshops that introduced K–12 students to engineering and human-centered design, reaching over 2,000 students across public schools and community events. She runs initiatives to broaden participation in computing and advises undergraduate students in outreach and curriculum development. Her lab collaborates with clinical partners and interdisciplinary teams to ensure real-world impact of her research.
Dr. Oana Cocarascu is a Senior Lecturer in Artificial Intelligence at the Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King's College London. She holds a PhD and MEng in Computing (Artificial Intelligence) from Imperial College London and conducts applied research focusing on how artificial intelligence can be deployed to support real-world applications, with machine learning and natural language processing as core components of her work. Her research interests span argument mining, explainable AI, machine learning, natural language processing, and symbolic reasoning. She is particularly focused on developing AI systems that can provide transparent, accountable, and ethical decision-making processes. Her work addresses critical challenges in bias mitigation, fairness metrics, fact verification systems, and argumentation-based explanations for complex AI decisions. Analysis of her recent publications (2023-2025) reveals a strong focus on fairness in AI systems, with particular attention to individual fairness metrics and nuanced evaluation frameworks. She has made significant contributions to fact verification systems, especially in multimodal contexts involving charts and tabular data. Her work increasingly integrates argumentation theory with natural language processing to create explainable AI systems that can justify their decisions through structured reasoning. Dr. Cocarascu leads an EPSRC-funded project titled 'A framework for evaluating and explaining the robustness of NLP models' (2024-2027) and is actively involved in the Natural Language Processing Group at KCL. Her research fingerprint shows strong activity in argumentation (100%), decision-making (74%), artificial intelligence (50%), explainable AI (39%), and bias mitigation (35%). She has contributed to numerous high-impact publications in top venues including ACL, EMNLP, AAAI, and the Journal of Artificial Intelligence Research, with a particular focus on making AI systems more transparent, accountable, and aligned with human values. Her work intersects with UN Sustainable Development Goals, particularly those related to reducing inequality and building resilient infrastructure.
Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Karen Piper Hanley is Professor of Molecular Medicine and Head of Division in the Division of Diabetes, Endocrinology & Gastroenterology at the University of Manchester. She serves as the fibrosis lead in the Wellcome Trust Centre for Cell-Matrix Research and previously served as Director of Core Research Technologies (2019-2022). She is also an editorial board member for Scientific Reports. Her research focuses on fibrosis (scarring) mechanisms across multiple organs, particularly liver, kidney, and lung fibrosis. Her lab investigates the cellular and molecular basis of fibrotic disease, with emphasis on how pathological scar components are produced and how they signal to surrounding cells. Key areas include the role of SOX9 transcription factor, integrin beta-1 signaling, Group 1 PAKs, and YAP1 in fibrosis progression. Her recent publications reveal trends toward increased clinical translation of fibrosis research, with studies on health inequalities in liver cancer care, post-COVID diabetes incidence, and innovative approaches to liver disease detection. Her work increasingly integrates spatial transcriptomics and advanced omics technologies to understand cellular transitions in liver disease. Career-track postdoctoral fellowship from the University of Southampton (2006) As senior postgraduate tutor, she has mentored numerous PhD students who have presented at key conferences and authored high-quality manuscripts. All her PhD students have submitted and been awarded their degrees within 4 years. She has successfully guided previous Academic Clinical Fellows to win MRC clinical training fellowships. Her teaching extends to undergraduate Personal & Professional Development and supervision of MRes and BSc students, many of whom have achieved first-class degrees and prestigious awards. Her lab maintains active collaborations with Professor Neil Hanley's group on human development, stem cells, and regenerative medicine, bridging developmental biology with fibrosis research to understand why regeneration is impaired in chronic diseases.
Johan Gustav Bellika is a Professor at the Department of Clinical Medicine, UiT The Arctic University of Norway, based in Tromsø. His work bridges clinical medicine with health informatics, focusing on practical applications that improve healthcare delivery and patient outcomes. Current Position: Professor, Department of Clinical Medicine Institution: UiT The Arctic University of Norway Location: Tromsø, Norway Contact: johan.gustav.bellika@uit.no Professor Bellika's research spans several critical areas in modern healthcare. His primary focus is on health informatics with particular emphasis on medical data privacy, electronic health records, and the application of artificial intelligence in clinical settings. He has made significant contributions to understanding chronic pain management through technology, primary care research networks, and patient-centered care models. His work often involves large population studies such as the Tromsø Study, examining how digital health tools impact healthcare utilization and patient outcomes. His research demonstrates a consistent thread connecting technological innovation with practical clinical applications. Bellika has been instrumental in developing privacy-preserving architectures for healthcare data analysis, which enable researchers to gain insights from sensitive health information without compromising patient privacy. His work on federated learning frameworks represents cutting-edge approaches to analyzing medical data while maintaining strict privacy controls. Health Informatics and Medical Data Privacy Chronic Pain Management through Technology Primary Care Research Networks (PraksisNett) Electronic Health Records and Clinical Decision Support Patient-Centered Digital Health Solutions Federated Learning Applications in Healthcare Professor Bellika's publication record shows a strong trend toward interdisciplinary research that combines clinical medicine, computer science, and public health. His recent work increasingly focuses on the intersection of artificial intelligence and healthcare, particularly how machine learning can be applied to chronic conditions while maintaining rigorous privacy standards. The geographical scope of his research extends across Norway with particular emphasis on Northern Norwegian populations, providing valuable insights into healthcare delivery in Arctic and remote regions. His collaborative approach is evident through numerous co-authored publications with researchers across multiple institutions and disciplines. While specific awards aren't detailed in the available information, his extensive publication record in reputable journals suggests recognition within his field. Professor Bellika has been actively involved in several major research initiatives including the Tromsø Study and PraksisNett, Norway's nationwide practice-based research network. His work on privacy-preserving architectures for healthcare data has significant implications for how medical research can be conducted while respecting patient confidentiality. He appears to be particularly focused on translating research findings into practical tools for clinicians, as evidenced by his work on audit and feedback systems for antibiotic prescribing.
Professor Brent Mittelstadt is a leading academic in data ethics and AI governance at the University of Oxford's Oxford Internet Institute (OII), serving as Professor of Data Ethics and Policy and Director of Research. He coordinates the Governance of Emerging Technologies (GET) programme, focusing on ethics, law, and technology interplay. His work bridges academic research with policy impact, contributing frameworks like 'counterfactual explanations' and fairness metrics ('Conditional Demographic Disparity') used globally. He leads high-profile projects such as Trustworthiness Auditing for AI and A Right to Reasonable Inferences in Advertising and Financial Services. Research interests span AI ethics, medical ethics, technology governance, and non-discrimination law. He has pioneered ethical frameworks addressing algorithmic bias, GDPR compliance, and AI accountability. His work has influenced policy bodies like the UK Information Commissioner’s Office and the European Commission, and is implemented by tech giants such as Google and Microsoft. Awarded O2RB Excellence in Impact Awards (2018, 2021) and PLSC Best Paper (2019) Funded by Wellcome Trust, Sloan Foundation, and others Advisory roles for NHSx, GSK Consumer Healthcare, and regulatory bodies Recent work focuses on AI regulation (EU AI Act), generative AI ethics, and healthcare AI governance. He co-leads the OxonFair toolkit for algorithmic fairness and investigates societal impacts of deepfake proliferation and large language models.
Dr. Birgit Frauscher is the Lincoln Financial Group Distinguished Professor in Neurobiology at Duke University School of Medicine, where she serves as Professor of Neurology and holds a secondary appointment in the Department of Biomedical Engineering at the Duke Pratt School of Engineering. She is currently the Director of the Duke Comprehensive Epilepsy Center and leads the Analytical Neurophysiology (ANPHY) Lab. Her clinical and research work focuses on epilepsy and sleep medicine, utilizing both invasive and non-invasive electrical recordings to study brain activity in humans. Dr. Frauscher completed her medical training, neurology residency, and subspecialty training in electroencephalography, epilepsy, and sleep medicine at the Medical University of Innsbruck in Austria. After completing her clinical training in 2008, she earned her habilitation degree in 2011. She further specialized in intracranial EEG and signal analysis during a visiting professorship at the Montreal Neurological Institute and Hospital, McGill University (2013-2015), where she later served as an Attending Epileptologist and Group Leader of Epilepsy. Her research interests focus on developing novel seizure-independent EEG markers for the epileptogenic zone, investigating sleep-epilepsy interactions, and using intracranial EEG to study brain physiology during wakefulness and sleep. Her work aims to improve epilepsy diagnosis, prognosis, and treatment outcomes by better localizing the epileptic focus. Dr. Frauscher's recent publications demonstrate her continued leadership in epilepsy research, with over 170 peer-reviewed papers and an H-index of 62. Dr. Frauscher has received several prestigious awards including the Clinician-Scientist awards of the FRSQ (2018-2023), the Michael Prize of the International League against Epilepsy (2019), and the Ernst Niedermeyer Prize from the Austrian Epilepsy Society (2015). Her scholarly work has significantly advanced clinical knowledge in epilepsy and sleep medicine, establishing her as a leading figure in the field. As Director of the Duke Comprehensive Epilepsy Center and head of the ANPHY lab, Dr. Frauscher oversees a research program dedicated to advancing neuroscience through innovative approaches to studying brain activity. Her lab employs quantifiable tools to investigate neurophysiological and pathological processes related to epilepsy and sleep, with the ultimate goal of improving patient outcomes through better understanding of brain function.
